GBGraham Beaton

Graham Beaton

*This is an algorithmically generated author record based on publicly available information.

Graham Beaton has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmacologic inhibition of OLIG2 by CT-179 disrupts mitotic progression and enhances standard-of-care chemoradiotherapy in glioblastoma

    by Sam A. Greenall, Shengnan C. Chen, Gordon Alton, Graham Beaton, Reghan Boelter, Mattie Casey, Ivan Babic, Zara C. Bruce, Daniel J. Garama, Rajesh Mukthavaram, et al.

    Background: Glioblastoma (GBM) remains uniformly fatal. The basic helix-loop-helix transcription factor OLIG2 is universally expressed in diffuse glioma, sustains the tumor-propagating stem-like fraction, and opposes p53-mediated genotoxic responses, but has historically been considered undruggable. We characterized CT-179, a brain-penetrant small-molecule OLIG2 inhibitor, as a candidate therapeutic for GBM. Methods: Target engagement was assessed by cellular thermal shift assay, differential scanning fluorimetry, crosslinking, and electrophoretic mobility shift assay. Anti-tumor activity was evaluated across eleven patient-derived GBM cell lines, in zebrafish oligodendrocyte precursor cell (OPC)-derived tumors, and orthotopic and subcutaneous GBM models, including combinations with radiotherapy plus temozolomide and with selective Bcl-2 family inhibitors. Results: CT-179 engaged OLIG2 and altered the conformation of dimerized OLIG2 on chromatin without preventing dimerization or fully displacing OLIG2 from DNA. CT-179 reduced OLIG2-positive OPC’s and OPC-derived tumors in zebrafish and inhibited proliferation across all eleven GBM lines (IC50 < 360 nM), depleting the stem-like fraction and inducing apoptosis through mitotic catastrophe, mitotic slippage, or a hybrid response. RNA-seq across three patient-derived glioma stem cell lines identified β-tubulin gene isoforms as the most strongly CT-179-down-regulated transcripts at the early time point and showed correlated β-tubulin and OLIG2 expression in TCGA glioblastoma specimens. Combination with the Mcl-1 inhibitor S63845 or the Bcl-2/Bcl-xL/Bcl-w inhibitor ABT-737 produced greater-than-additive cytotoxicity. Oral CT-179 crossed the blood-brain barrier and extended median survival as a single agent across two independent adult orthotopic patient-derived backgrounds (GBM8 and G06); intraperitoneal CT-179 was associated with reduced intratumoral OLIG2 and Ki-67 staining in GBM8 orthotopic xenografts. Combination of CT-179 with radiotherapy and temozolomide eliminated all GBM8 and 7 of 8 GBM4 subcutaneous xenografts without weight loss and significantly extended survival when combined with radiotherapy in MGMT-unmethylated GBM6 orthotopic xenografts (CT-179 administered intraperitoneally). Conclusions: CT-179 is a brain-penetrant inhibitor of an established GBM driver with single-agent and combination activity across several orthotopic models, supporting clinical development for GBM and translational evaluation in other OLIG2-dependent CNS malignancies. Key Points: CT-179 is the first brain-penetrant small-molecule inhibitor of OLIG2 with potent activity across patient-derived glioblastoma models. CT-179 induces apoptosis through mitotic catastrophe and slippage rather than collapse of receptor tyrosine kinase signaling. Oral CT-179 combined with radiotherapy and temozolomide eliminates the great majority of subcutaneous patient-derived GBM xenografts without overt toxicity. Oral CT-179 extends single-agent survival across two independent adult orthotopic patient-derived backgrounds (GBM8 and G06); intraperitoneal CT-179 is associated with reduced intratumoral OLIG2 and Ki-67 staining in GBM8 tumors. Intraperitoneal CT-179 plus radiotherapy significantly extends survival in an MGMT-unmethylated GBM6 orthotopic model where temozolomide contributes minimally and supports the rationale for further evaluation in MGMT-unmethylated GBM. Importance of the Study: Glioblastoma is uniformly fatal, and durable disease-modifying therapies that disable the lineage transcription factor programs sustaining the GBM stem-like state have remained elusive. OLIG2 is universally expressed in diffuse glioma and is a central driver of stemness, lineage-restricted RTK signaling, and resistance to genotoxic therapy, yet has historically been considered undruggable. This study reports the foundational preclinical characterization of CT-179, a brain-penetrant small molecule that engages OLIG2 directly and induces glioblastoma cell death through disrupted mitotic progression. Oral CT-179 crosses the blood-brain barrier, prolongs survival in orthotopic patient-derived xenografts, and substantially enhances the efficacy of standard-of-care radiotherapy and temozolomide. Activity in an MGMT-unmethylated orthotopic patient-derived GBM model in combination with radiotherapy is of particular translational interest, since this is the patient population for which temozolomide contributes minimally and the unmet need is greatest. These data establish proof of concept for direct pharmacologic inhibition of OLIG2 in GBM and provide a translational rationale, including an MGMT-stratified combination strategy, for combining CT-179 with current standard-of-care chemoradiotherapy. Lay Summary: Glioblastoma is the most common and aggressive brain cancer in adults, and almost all patients die of their disease. One reason is a protein called OLIG2, which keeps tumor cells in an immature, treatment-resistant state and has long been considered impossible to target with drugs. We studied CT-179, a small molecule that enters the brain and blocks OLIG2. In glioblastoma cells and in mice, CT-179 forced dividing tumor cells into a faulty, lethal division, extended survival on its own, and strengthened the effect of standard radiation and chemotherapy. These results support testing CT-179 in people with glioblastoma.

  • Open Access

    Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models

    by Jashdeep Bhattacharjee, Graham Beaton, Satheesh B. Ravula, Suk Joong Lee, Kevin B. Bacon, Celia P. Jenkinson, Mikako Warren, Fabio C. Tucci, Rohit Kohli

    Background: NASH causes a tremendous health care burden in the United States. A glucagon-like peptide-1 agonist, semaglutide (Sema), treatment resulted in hepatic steatosis reduction in clinical trials of NASH. Lysophosphatidic acid receptor 1 antagonists are known to have antifibrotic effects in several organs. We tested Sema and a novel lysophosphatidic acid receptor 1 antagonist, EPGN2154, individually and in combination to evaluate their efficacy for NASH remission in preclinical models. Methods: In the present study, we used (1) C57Bl6/J wild-type mice fed on a high-fat, high-carbohydrate (HFHC) diet for 16 weeks and (2) leptin-deficient mice (ob/ob) fed on an Amylin liver NASH diet for 16 weeks. After 16 weeks, the mice were randomly distributed in equal numbers in (1) no-drug, (2) EPGN2154, (3) Sema, and (4) EPGN2154+Sema treatment groups for 8 additional weeks at a dosage of 10 mg/kg body weight for EPGN2154 (oral gavage, 5 days a week) and 6.17 μg/kg body weight of Sema (subcutaneous injection every alternate day, 3 days a week). Results: In the wild-type-high-fat, high-carbohydrate model, we observed the most body weight loss in the EPGN2154+Sema combination group compared to the other treatment groups. All groups led to a significant reduction in alanine transaminase levels when compared to high-fat, high-carbohydrate–fed wild type. However, no significant difference in alanine transaminase levels was observed among the treatment groups. In the ob/ob mice study, Sema did not cause body weight loss. Moreover, the EPGN2154 and the combination groups had a lower NAFLD Activity Score and incidence of advanced-stage hepatic fibrosis than the Sema group. Conclusions: EPGN2154 demonstrated a hepato-protective effect independent of body weight loss in preclinical NASH models. Export


  • Top Cited Papers
    Open Access

    Normalization of cholesterol metabolism in spinal microglia alleviates neuropathic pain

    by Juliana M. Navia-Pelaez, Soo-Ho Choi, Luciano dos Santos Aggum Capettini, Yining Xia, Ayelet Gonen, Colin Agatisa-Boyle, Lauriane Delay, Gilson Gonçalves dos Santos, Glaucilene F. Catroli, Jungsu Kim, et al.

    Neuroinflammation is a major component in the transition to and perpetuation of neuropathic pain states. Spinal neuroinflammation involves activation of TLR4, localized to enlarged, cholesterol-enriched lipid rafts, designated here as inflammarafts. Conditional deletion of cholesterol transporters ABCA1 and ABCG1 in microglia, leading to inflammaraft formation, induced tactile allodynia in naive mice. The apoA-I binding protein (AIBP) facilitated cholesterol depletion from inflammarafts and reversed neuropathic pain in a model of chemotherapy-induced peripheral neuropathy (CIPN) in wild-type mice, but AIBP failed to reverse allodynia in mice with ABCA1/ABCG1–deficient microglia, suggesting a cholesterol-dependent mechanism. An AIBP mutant lacking the TLR4-binding domain did not bind microglia or reverse CIPN allodynia. The long-lasting therapeutic effect of a single AIBP dose in CIPN was associated with anti-inflammatory and cholesterol metabolism reprogramming and reduced accumulation of lipid droplets in microglia. These results suggest a cholesterol-driven mechanism of regulation of neuropathic pain by controlling the TLR4 inflammarafts and gene expression program in microglia and blocking the perpetuation of neuroinflammation.


  • Systemic TAK-242 prevents intrathecal LPS evoked hyperalgesia in male, but not female mice and prevents delayed allodynia following intraplantar formalin in both male and female mice: The role of TLR4 in the evolution of a persistent pain state

    by Sarah A. Woller, Satheesh B. Ravula, Fabio C. Tucci, Graham Beaton, Maripat Corr, R. Rivkah Isseroff, Athena M. Soulika, Marianne Chigbrow, Kelly A. Eddinger, Tony L. Yaksh


  • The expanding role of H1antihistamines: a patent survey of selective and dual activity compounds 2005 – 2010

    by Graham Beaton, Wilna J Moree

    Importance of the field: Histamine plays a key role in physiological processes through its interaction with H1 – 4 histamine receptors. The H1 receptor is a key element in the pathophysiology of allergic responses. H1 antihistamine use is a key strategy for therapy in allergy.Areas covered in this review: Several new chemical entities with improved efficacy in allergic disease have been pursued. Addition of multiple antagonist activities in single compounds has been the focus of current research. Involvement of the H1 receptor in sleep has led to the evaluation of new compounds as sedative hypnotics.What the reader will gain: In all, 57 patents detail the evolution of new chemical entities. Dual H1–CC-chemokine receptor-3 and H1 – H3 antagonists have entered the clinic for allergic indications. Efforts to develop H1 antihistamines as sedative hypnotics have increased, with several compounds entering the clinic. The dual H1–5-HT2A antagonist doxepin has been approved for sleep disorders while another compo...